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Preliminary Report
Iron Homeostasis during Cystic Fibrosis Pulmonary Exacerbation
Alex H. Gifford, M.D.1, Lisa A. Moulton, R.N.1, Dana B. Dorman, R.N.1, Gordana Olbina, Ph.D.2, Mark Westerman, Ph.D.2, H. Worth Parker,
M.D.1, Bruce A. Stanton, Ph.D.3, and George A. O’Toole, Ph.D.3
Abstract
Background: Hypoferremia is a marker of disease severity in cystic fibrosis (CF). The effect of systemic antibiotics on iron homeostasis
during CF pulmonary exacerbation (CFPE) is unknown. Our central hypotheses were that, by the completion of treatment, serum iron
would increase, serum concentrations of interleukin-6 (IL-6) and hepcidin-25, two mediators of hypoferremia, would decrease, and
sputum iron would decrease.
Methods: Blood and sputum samples were collected from 12 subjects with moderate-to-severe CF (median percentage-predicted
forced expiratory volume in 1 second (FEV1%) = 29%; median weight = 56 kg) within 24 hours of starting and completing a course
of systemic antibiotics.
Results: After treatment, subjects showed median FEV1% and body weight improvements of 4.5% and 2.0 kg, respectively (p < 0.05).
Median serum iron rose by 2.4 µmol/L (p < 0.05), but 75% of patients remained hypoferremic. Median serum IL-6 and hepcidin-25
levels fell by 12.1 pg/mL and 37.5 ng/mL, respectively (p < 0.05). Median serum erythropoietin (EPO) and hemoglobin levels were
unaffected by treatment. We observed a trend toward lower sputum iron content after treatment.
Conclusions: Hypoferremia is a salient characteristic of CFPE that improves with waning inflammation. Despite antibiotic treatment,
many patients remain hypoferremic and anemic because of ineffective erythropoiesis. Clin Trans Sci 2012; Volume 5: 368–373

Keywords: iron, hepcidin, cystic fibrosis, interleukin-6, exacerbation
Introduction

Cystic fibrosis (CF) is a lethal genetic disease in which dysfunction
of the CF transmembrane conductance regulator (CFTR) chloride
channel in bronchial epithelial cells prevents hydration of airway
surface liquid (ASL) in the lung. These thick secretions are a
favorable environment for bacterial colonization, which incites
chronic inflammation and eventual respiratory failure from
bronchiectasis. The natural history of CF is characterized by
acute exacerbations during which patients experience new or
worsened respiratory and constitutional symptoms referable
to infection.1 Although no consensus definition exists for CF
pulmonary exacerbation (CFPE),2 the phenomenon is associated
with accelerated lung function decline and premature death.3,4
At 3 months after intravenous antibiotics for CFPE, 25% of
patients in a large cohort failed to regain their baseline percentagepredicted forced expiratory volume in 1 second (FEV1%), a key
spirometric endpoint in CF, as averaged over the 6 months before
CFPE. Persistent infection by Pseudomonas aeruginosa (PA) was
an independent risk factor for this irreversible impairment.5
Growth within antibiotic-resistant biofilm communities is one
means by which PA persists in the CF lung.6 Polarized bronchial
epithelial cells that express dysfunctional CFTR release iron
into ASL, which augments the overlying growth of PA biofilms.7
Hence, abnormal iron handling by airway epithelial cells likely
contributes to PA lung infection in CF.
Clinical studies support the premise that iron homeostasis is
uniquely aberrant in this disease. The iron content of CF sputum
is approximately 2.5–5.5 times higher than sputum from patients
with chronic obstructive pulmonary disease (COPD) and about
3.4–4.2 times higher than sputum from normal controls.8–10 Reid
et al.11 reported a significant direct relationship between sputum
iron and quantitative culture of PA, suggesting that its growth
is related to iron availability. Three investigations9–11 with a total
of 34 subjects have revealed that sputum iron content does not
change after CFPE therapy, but none of them addressed ironrelated hematologic parameters.

Excess lung iron in CF presumably originates from host reserves
despite complex regulatory mechanisms governing its uptake,
utilization, and storage. Iron is necessary for oxygen transport by
hemoglobin, mitochondrial energetics, and modulation of gene
transcription.12 Its absorption from dietary sources by duodenal
enterocytes is markedly reduced during states of inflammation
and systemic iron overload by the activity of hepcidin-25.13 This
polypeptide hormone of hepatic origin triggers the degradation
of the iron-exporting protein ferroportin in mononuclear cells
and enterocytes resulting in iron sequestration and attenuated
uptake, respectively.14,15 By these mechanisms, hepcidin-25 lowers
blood iron, a condition called hypoferremia. Interleukin-6 (IL-6)
potently stimulates hepcidin-25 production16 thereby linking iron
regulatory pathways to the inflammatory milieu. The hepcidinIL-6 axis has heretofore not been investigated in CF.
The main goal of this study was to characterize how CFPE
treatment influences iron handling in the circulatory and airway
compartments given a paucity of data from concurrent assessment.
Based on the available literature and our findings, we hypothesized
that CFPE treatment would be associated with higher iron, and
lower hepcidin-25 and IL-6 serum concentrations. Moreover,
we postulated that sputum iron content would fall in response
to treatment.
Methods

Definitions
CFPE was defined by new or acutely worsened sinopulmonary
and constitutional signs and symptoms that included the
following: increased cough frequency, increased daily sputum
expectoration, wheezing, dyspnea, fevers, chills, sweating,
anorexia, and weight loss.17 An attending pulmonologist with
longitudinal experience in caring for a given subject determined
whether CFPE was apparent. Early CFPE was a point <24 hours
after CFPE determination, and late CFPE was a point <24 hours
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before finishing treatment. No subject received more than two
scheduled doses of systemic antibiotics before drawing blood at
the early CFPE time point. The duration of hospitalization was
not specified a priori and was influenced by how long the subject
wanted to remain in the hospital and the attending physician’s
appraisal of clinical progress. We defined hypoferremia according
to other CF studies17–19 as a serum iron ⱕ12 μmol/L, a threshold
below which erythropoiesis becomes iron limited.20 A hemoglobin
level <13.7 g/dL, the lower limit of the reference range for our
laboratory, established a diagnosis of anemia.

For samples in which the concentration of IL-6 was undetectable,
the lower limit of detection (1.9 pg/mL) was used in statistical
analyses.

Enrollment
Blood and sputum samples were obtained from 12 adults with CF
during early and late CFPE after provision of informed consent.
The Committee for the Protection of Human Subjects (CPHS)
at Dartmouth College approved the study protocol. Age ≥18
years and a history of PA airway colonization were inclusion
criteria. Subjects were not eligible to participate if they were
taking supplemental iron and if inclusion criteria were not
satisfied. All subjects were treated with dual systemic antibiotics
against PA based on susceptibility testing from the most recent
sputum culture. No subject received iron supplementation or
transfusion of packed red blood cells. Two subjects were using
systemic corticosteroids or nonsteroidal antiinflammatory drugs
before hospital admission, and these were continued without dose
escalation. Sputum samples were spontaneously expectorated
(i.e., not induced by inhalation of hypertonic saline) and were
excluded from trace element analysis if any blood was visible.
Routine chest physiotherapy and consultation with a nutritionist
and a diabetes nurse specialist (if applicable) were offered to all
subjects. The volume of blood drawn at each time point (i.e., early
and late CFPE) was approximately 25 mL.

Data analysis
Data are presented as medians and ranges unless otherwise noted.
Biochemical parameters for each patient during early and late
CFPE were compared using the Wilcoxon matched-pairs signedrank test. The strength of association between nominal variables
is given by Spearman rank correlation (ρ). A two-tailed p-value
of <0.05 was considered statistical significant. GraphPad Prism®
5.0 (GraphPad Software, San Diego, CA, USA) was used for all
analyses.

Measurement of complete blood counts and serum iron
Complete blood counts were done using a Sysmex XE-2100
autoanalyzer (Sysmex America, Inc., Mundelein, IL, USA). Serum
iron was determined using a COBAS c311 autoanalyzer (Roche
Diagnostics USA, Indianapolis, IN, USA).
Measurement of serum hepcidin-25
Serum hepcidin-25, the physiologically active polypeptide
hormone of iron regulation, was quantified according to an
established protocol21 at Intrinsic LifeSciences, LLC (LaJolla,
CA, USA). Briefly, the technique is a competitive enzymelinked immunosorbant assay (C-ELISA) using biotinylation as
a detection method. Samples were analyzed in duplicate, and
mean values were used in subsequent calculations. The lower
limit of detection was 5 ng/mL.
Measurement of serum erythropoietin
Serum erythropoietin (EPO) was measured using a commercially
available double-sandwich ELISA (Quantikine® IVD®, R&D
Systems, Inc., Minneapolis, MN, USA), according to the
manufacturer’s instructions. Samples were analyzed singly. The
lower limit of detection was 2.5 mU/mL.

Measurement of sputum iron
Whole sputum plugs were weighed and digested with a standard
volume of nitric acid. Total inorganic iron in each aliquot was
quantified by inductively coupled plasma–mass spectroscopy
(ICP–MS)17 and is expressed as nanograms of iron per milligram
of sputum.

Results

Patients and treatment
Clinical attributes of the cohort at the time of CFPE
determination are listed in Table 1. The median age of the cohort
was 32 years. In general, patients had severe pulmonary function
impairment, nutritional insufficiency, CF-related diabetes,
hypoferremia, and mild anemia, a chronic illness phenotype
that we described in a larger cross-sectional study.17 Fifty-eight
percent of patients possessed two F508-CFTR alleles, which
is similar to the frequency of homozygosity for this mutation
in Caucasians.22 Patients received antibiotics for a median of
12 days (range: 5–19), which is congruent with pervasive
practice patterns.23
CFPE Treatment is associated with weight gain and improved
lung function
We compared clinical parameters for subjects in early versus
late CFPE. In all cases, early CFPE was a point <24 hours after
CFPE determination, and late CFPE was a point <24 hours before
finishing treatment. Median increases in body weight and FEV1%
were 2.0 kg and 4.5%, respectively (p < 0.01 for late CFPE vs.
early CFPE; Figures 1A and B). Body weight and FEV1% were
N = 12
Age (years)
Gender (M/F)
FEV1 (% predicted)
Body weight (kg)

WWW.CTSJOURNAL.COM

9/3
29 (21–48)a
55.5 (40.2–75.1)a

⌬F508-CFTR homozygote

7 (58)b

CF-related diabetes

11 (92)b

Serum iron (µmol/L)

Measurement of serum IL-6
Serum IL-6 was quantified using Bio-Plex human cytokine
multiplex kits (Bio-Rad Inc., Hercules, CA, USA), according
to the manufacturer’s instructions. Samples were analyzed in
triplicate, and mean values were used in subsequent calculations.

32 (18–53)a

Hemoglobin (g/dL)

4.8 (1.6–16.1)a
12.9 (10.1–15.2)a

CFPE = CF pulmonary exacerbation. Data are presented as median and (ranges) a or
number of subjects and (percentages) b.

Table 1. Clinical characteristics of subjects at early CFPE.
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significantly correlated at early
CFPE (ρ = 0.76, p < 0.01) but
not at late CFPE. FEV1% directly
correlated with serum iron at
early CFPE (ρ = 0.58) and late
CFPE (ρ = 0.65; p < 0.05 for both
correlations).
CFPE treatment is associated
with higher serum and lower
sputum iron concentrations
Our previous work indicated a
link between high serum iron,
low sputum iron, and increased
FEV1%. Therefore, we assessed
these parameters in CFPE subjects
before and after treatment with
IV antibiotics. According to our
definition of hypoferremia (serum
iron ⱕ12 μmol/L), 10 of 12 subjects
(83%) were hypoferremic at early
CFPE. Median serum iron rose by
2.42 μmol/L (13.5 mg/dL) by the
end of therapy (Figure 2A). All
but one of the subjects who were
hypoferremic at early CFPE had
serum iron readings <12 μmol/L
at late CFPE and thus, remained
iron-deficient. Only 9 of 12 subjects
(75%) who furnished sputum
samples at early CFPE were able
to provide follow-up samples at
late CFPE, which is not unusual
for patients after completing a
course of intravenous antibiotics.
Among these subjects, median
sputum iron fell by 0.92 ng/mg,
a value that approached but did
not attain significance at a 95%
CI (p = 0.055; Figure 2B). Serum
and sputum iron did not correlate
significantly at early or late CFPE,
which is a similar finding to our
cross-sectional analysis of these
parameters.17

Figure 1. Changes in body weight and FEV1% during treatment. Median values are denoted by the line within each shaded box.
The upper and lower boundaries of the shaded box reflect the interquartile range of data. Whiskers signify minimum and maximum values. **p < 0.01 for comparison by Wilcoxon matched-pairs signed-rank test. CFPE = CF pulmonary exacerbation.

Figure 2. Changes in serum iron and sputum iron during treatment. Median values are denoted by the line within each
shaded box. The upper and lower boundaries of the shaded box reflect the interquartile range of data. Whiskers signify minimum and maximum values. *p < 0.05 for comparison by Wilcoxon matched-pairs signed rank test. CFPE = CF pulmonary
exacerbation.

CFPE treatment is associated
with lower serum hepcidin-25
and IL-6 levels
We next quantified known
mediators of iron homeostasis
to explore possible mechanisms
by which serum iron increased Figure 3. Changes in serum IL-6 and hepcidin-25 during treatment. IL-6 = interleukin-6. Median values are denoted by the line
within each shaded box. The upper and lower boundaries of the shaded box reflect the interquartile range of data. Whiskers
posttreatment. Median serum IL-6 signify minimum and maximum values. *p < 0.05, **p < 0.01 for comparison by Wilcoxon matched-pairs signed-rank test.
fell by 12.1 pg/mL (p < 0.05 for late CFPE = CF pulmonary exacerbation. Note: logarithmic scale of ordinate.
CFPE vs. early CFPE; Figure 3A).
Median serum hepcidin-25 was
37.5 ng/mL lower at late CFPE (p < 0.01) (Figure 3B). Serum
CFPE treatment does not influence hemoglobin and serum
iron did not correlate with hepcidin-25 at either time point during
erythropoietin
CFPE; however, serum IL-6 was indirectly correlated with serum
Given the observed changes in serum iron and regulators of
iron at late CFPE (ρ = –0.66, p < 0.05).
iron homeostasis posttreatment, we next assessed the impact of
370
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more or less dramatically to the
endpoints of better lung function
and weight gain. Subjects not
only received dual systemic
antibiotic coverage for PA but also
nutritional supplementation and
daily airway clearance sessions to
mitigate secretions. The majority
of the cohort was diabetic, and as
such, received insulin for glycemic
control. Because these therapies
represent standards-of-care in CF,
it will be difficult to evaluate how a
Figure 4. Changes in hemoglobin and serum erythropoietin during treatment. Median values are denoted by the line within specific modality influences these
each shaded box. The upper and lower boundaries of the shaded box reflect the interquartile range of data. Whiskers signify metrics.2,27
minimum and maximum values. CFPE = CF pulmonary exacerbation. EPO = erythropoietin.
To our knowledge, this is
the first investigation to show
that serum iron increases in response to CFPE therapy and the
these changes on anemia. During the treatment interval, median
first to offer insights into possible mechanisms for this finding
hemoglobin increased by only 0.1 gm/dL (Figure 4A). The median
by examining trends in hepcidin-25 and IL-6. Cross-sectional
serum EPO concentration rose by 2.1 mU/mL (Figure 4B).
analyses18,28 of CF patients with varying disease severity report
Neither difference was statistically significant. Serum iron directly
that hypoferremia has a prevalence of 62–74%. Applying a similar
correlated with hemoglobin at early CFPE (ρ = 0.87, p < 0.01) and
definition of iron deficiency to two adult CF cohorts, we found
late (ρ = 0.58, p < 0.05) CFPE. Sputum iron did not correlate with
that subjects who recently experienced clinical deterioration had
hemoglobin. Thus, the observed changes in iron and mediators of
higher IL-6 and lower iron levels in plasma than those in good
iron homeostasis had no discernable effects on anemia.
health,17 which led us to suspect that IL-6 mediates hypoferremia
Discussion
in this disease. Nixon et al.29 found that mean serum IL-6 in 12
This prospective study was done to characterize iron homeostasis
patients with CFPE fell by 5.12 pg/mL (p < 0.01) after antibiotics,
within the context of CFPE, periods of acutely compromised health
but they did not investigate how reductions in this cytokine related
that frequently occur in this disease and adversely affect prognosis.
to changes in serum iron, hepcidin-25, and hemoglobin. Therefore,
In a small cohort of adults treated with antibiotics and supportive
the median reduction in serum IL-6 that we observed (12.1 pg/mL)
care, we found that improved lung function and weight gain were
not only supports their observation but also highlights its clinical
associated with higher serum iron and lower circulating levels of
relevance by demonstrating how IL-6 relates to other biomarkers
mediators known to restrict iron bioavailability. Most of the subjects
of iron homeostasis in CF.
remained hypoferremic and mildly anemic despite statistically
We can find no published data supporting the contention that
significant increases in serum iron. We observed a trend toward
CFPE onset is heralded by increases in sputum iron. However, data
lower sputum iron content after treatment in 9 of the 12 subjects
from 34 subjects in 3 studies9–11 suggest that sputum iron does not
change significantly after antibiotics. Using a colorimetric assay to
for whom samples were available from early and late CFPE.
quantify total iron in denatured sputum samples from 14 patients,
Studies focusing on CFPE treatment responses are
Reid et al.9 found that median iron content was not different
methodologically diverse; however, those in which intravenous
between the outset (47 μmol/L) and the end (33 μmol/L) of therapy
antibiotics are used and changes in FEV1% and body weight are
reported, as in our study, demonstrate that these parameters
(p = 0.1). The median duration of antibiotic administration in this
improve modestly and commensurately.24,25 Therefore, our
study9 was 12 days, which compares favorably with our median
subjects’ treatment responses were not unusual. According to
treatment interval (12 days). In six additional patients, Reid
the 2010 CF Foundation patient registry, the median duration
et al.11 demonstrated that sputum iron was unaltered after a median
of 8 antibiotic days (35.3 μmol/L vs. 35.6 μmol/L, p > 0.05). For
of intravenous antibiotic therapy for adults with CFPE in the
a cohort of 14 patients, Gray et al.10 used ICP-MS to show that
United States was 14.7 days, with a range of 7.8–23.3 days.26
The median in our study was 12 days with a range of 5–19 days,
sputum iron, unlike sputum zinc, did not fall significantly after
slightly shorter than nationwide medical practice. Treatment
CFPE therapy, although they do not provide the sputum iron data
duration certainly could impact the extent to which biomarkers
and do not comment on treatment modalities or their duration.
of iron homeostasis vary. Nonetheless, in our study, the subject
Herein, we identified a trend toward lower sputum iron at the end
with the shortest treatment interval (5 days) still experienced a
of CFPE treatment in 9 of 12 subjects. A lack of paired samples
0.5 kg increase in body weight, a 6% improvement in FEV1%, a
for iron quantification in three instances is clearly a source of
1.79 μmol/L increase in serum iron, and reductions in serum IL-6
type II error that limits our ability to ascertain whether CFPE
and hepcidin-25 of 2 pg/mL and 104.9 ng/mL, respectively. These
treatment reduces sputum iron. However, our observation that
trends are similar to those observed among subjects treated for
CFPE treatment does not change this parameter could also be
longer periods. Discerning how the length of therapy influences
consistent with the findings of the aforementioned authors.9–11
Future investigations of sputum iron trends in CF should ensure
iron homeostasis during CFPE will require a study in which this
uniformity of analytical techniques and treatment length and be
parameter is controlled.
adequately powered to detect a prespecified change in response
A significant limitation of our work is the inability to distinguish
to a specific intervention.
which interventions in a multifaceted regimen contributed
WWW.CTSJOURNAL.COM
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ICP–MS, the technique employed herein to measure total
iron in each sputum aliquot, does not provide information about
how the metal is distributed within the sample. The amount of
iron in CF sputum could be proportional to the quantitative PA
burden, as Reid et al.11 advance, but it could also reflect iron
bound to human airway proteins like ferritin and lactoferrin
and to bacterial iron-scavenging molecules called siderophores.30
Regardless of the metal’s distribution, lower total sputum iron
following CFPE treatment is theoretically advantageous because
PA biofilm growth is augmented by iron.7
We provide evidence for ineffective erythropoiesis during
CFPE, as hemoglobin levels were unaltered by treatment. Our data
suggest two possible explanations for persistent anemia: serum
iron was insufficient to support erythropoiesis and/or serum EPO
did not adequately stimulate the growth and differentiation of
erythrocyte precursors in the face of greater iron bioavailability.
The former explanation is most likely given that erythropoiesis is
impaired at serum iron levels ⱕ12 μmol/L,20 and serum iron did
not exceed this value in 75% of patients after treatment.
Our study design does not account for the potential effect
of routine phlebotomy on lowering hemoglobin. Serial blood
sampling for diagnostic tests can cause “iatrogenic” or “nosocomial”
anemia during hospital admission, mainly because collected
blood volumes often far exceed the minimum amount necessary
for satisfactory assay performance.31 For several reasons, this
bloodletting phenomenon is unlikely to have contributed to our
finding that median hemoglobin concentration did not increase
by late CFPE. First, we obtained roughly 25 mL of blood at each
of the two CFPE time points. A retrospective analysis of factors
that significantly contributed to changes in hemoglobin values
among general medical inpatients found that for every 50 mL of
blood removed by phlebotomy, mean hemoglobin concentration
would be expected to fall by 0.35 g/dL (95% CI, 0.24–0.46).32
Median hemoglobin at late CFPE was actually a bit higher than
at early CFPE (Figure 4A). Second, our subjects did not represent
a hospitalized population at risk for large-volume phlebotomy.
Wisser et al.33 reported that iatrogenic blood loss of >200 mL is
almost exclusively observed in patients with long-term mechanical
ventilation, coagulation disorders, and repeated surgery. These
features do not apply to the CF subjects in our study.
In conclusion, we found that recovery from CFPE is
associated with higher serum iron levels, weight gain, and better
lung function. The waning inflammatory milieu, as reflected by
lower posttreatment serum hepcidin-25 and IL-6 concentrations,
likely underlies the significant improvement in hypoferremia.
Despite an increase in circulating iron reserves after treatment,
a significant erythropoietic response was not identified. Our
finding of no statistically significant reduction in sputum iron
after antibiotics is consistent with several studies.9–11 These
findings raise the possibility that biochemical measures of iron
homeostasis, particularly those from blood samples, could be used
as surrogate endpoints in the design of CF treatment trials.
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